Receptor-Mediated Uptake of Phosphorothioate Antisense Oligonucleotides in Different Cell Types of the Liver

Nucleic Acid Therapeutics

Volumn 28, Issue 3, 2018, Pages 119-127

  Miller, Colton M ^a   Tanowitz, Michael ^b   Donner, Aaron J ^b   Prakash, Thazha P ^b   Swayze, Eric E ^b   Harris, Edward N ^a   Seth, Punit P ^b  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

asialoglycoprotein receptor; hepatocytes; sinusoidal endothelial cells; Stabilins

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ASIALOGLYCOPROTEIN RECEPTOR; PHOSPHOROTHIOIC ACID; RECEPTOR; SCAVENGER RECEPTOR A; GLYCOCONJUGATE; N ACETYLGALACTOSAMINE; NERVE CELL ADHESION MOLECULE; OLIGONUCLEOTIDE PHOSPHOROTHIOATE; SMALL INTERFERING RNA; STAB1 PROTEIN, MOUSE;

ARTICLE; BIOLOGICAL ACTIVITY; CELLS BY BODY ANATOMY; ENDOCYTOSIS; ENDOTHELIUM CELL; HUMAN; KUPFFER CELL; LIVER CELL; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; ANIMAL; CELL ENGINEERING; CYTOLOGY; GENE TRANSFER; GENETICS; HEK293 CELL LINE; LIVER; METABOLISM; MOUSE; PROCEDURES;

ACETYLGALACTOSAMINE; ANIMALS; ASIALOGLYCOPROTEIN RECEPTOR; CELL ADHESION MOLECULES, NEURONAL; CELL ENGINEERING; ENDOCYTOSIS; ENDOTHELIAL CELLS; GENE TRANSFER TECHNIQUES; GLYCOCONJUGATES; HEK293 CELLS; HEPATOCYTES; HUMANS; KUPFFER CELLS; LIVER; MICE; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; RNA, SMALL INTERFERING; SCAVENGER RECEPTORS, CLASS A;

EID: 85048371489     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2017.0709     Document Type: Article

References (85)

1. Eckstein F. (2014). Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther 24:374-387.
2. Stein CA, C Subasinghe, K Shinozuka and JS Cohen. (1988). Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res 16:3209-3221.
3. Liang X-H, H Sun, W Shen and ST Crooke. (2015). Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res 43:2927-2945.
4. Vickers TA and ST Crooke. (2016). Development of a quantitative BRET affinity assay for nucleic acid-protein interactions. PLoS One 11:e0161930.
5. Geary RS, RZ Yu and AA Levin. (2001). Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. Curr Opin Investig Drugs 2:562-573.
6. Beltinger C, HU Saragovi, RM Smith, L LeSauteur, N Shah, L DeDionisio, L Christensen, A Raible, L Jarett and AM Gewirtz. (1995). Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J Clin Invest 95:1814-1823.
7. Sehgal A, A Vaishnaw and K Fitzgerald. (2013). Liver as a target for oligonucleotide therapeutics. J Hepatol 59:1354-1359.
8. Knolle P. (2007). Role and function of liver sinusoidal endothelial cells. In: Liver Immunology. Gershwin ME, J Vierling and M Manns, eds. Humana Press, New York, pp. 25-39.
9. Butler M, K Stecker and CF Bennett. (1997). Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest 77:379-388.
10. Bijsterbosch MK, M Manoharan, ET Rump, RL De Vrueh, R van Veghel, KL Tivel, EA Biessen, CF Bennett, PD Cook and TJ van Berkel. (1997). In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 25:3290-3296.
11. Sorensen KK, J Simon-Santamaria, RS McCuskey and B Smedsrod. (2015). Liver sinusoidal endothelial cells. Compr Physiol 5:1751-1774.
12. Braet F and E Wisse. (2002). Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 1:1-17.
13. Blouin A, RP Bolender and ER Weibel. (1977). Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study. J Cell Biol 72:441-455.
14. Wisse E, F Braet, D Luo, R De Zanger, D Jans, E Crabbe and A Vermoesen. (1996). Structure and function of sinusoidal lining cells in the liver. Toxicol Pathol 24:100-111.
15. Wisse E. (1970). An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastruct Res 31:125-150.
16. Enomoto K, Y Nishikawa, Y Omori, T Tokairin, M Yoshida, N Ohi, T Nishimura, Y Yamamoto and Q Li. (2004). Cell biology and pathology of liver sinusoidal endothelial cells. Med Electron Microsc 37:208-215.
17. Pempe EH, Y Xu, S Gopalakrishnan, J Liu and EN Harris. (2012). Probing structural selectivity of synthetic heparin binding to stabilin protein receptors. J Biol Chem 287: 20774-20783.
18. Miller CM, AJ Donner, EE Blank, AW Egger, BM Kellar, ME Ostergaard, PP Seth and EN Harris. (2016). Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. Nucleic Acids Res 44: 2782-2794.
19. Goerdt S, LJ Walsh, GF Murphy and JS Pober. (1991). Identification of a novel high molecular weight protein preferentially expressed by sinusoidal endothelial cells in normal human tissues. J Cell Biol 113:1425-1437.
20. Irjala H, K Alanen, R Grenman, P Heikkila, H Joensuu and S Jalkanen. (2003). Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res 63:4671-4676.
21. Goerdt S, R Bhardwaj and C Sorg. (1993). Inducible expression of MS-1 high-molecular-weight protein by endothelial cells of continuous origin and by dendritic cells/macrophages in vivo and in vitro. Am J Pathol 142:1409-1422.
22. Szekanecz Z, GK Haines, TR Lin, LA Harlow, S Goerdt, G Rayan and AE Koch. (1994). Differential distribution of intercellular adhesion molecules (ICAM-1, ICAM-2, and ICAM-3) and the MS-1 antigen in normal and diseased human synovia. Their possible pathogenetic and clinical significance in rheumatoid arthritis. Arthritis Rheum 37: 221-231.
23. Kzhyshkowska J, A Gratchev, JH Martens, O Pervushina, S Mamidi, S Johansson, K Schledzewski, B Hansen, X He, et al. (2004). Stabilin-1 localizes to endosomes and the trans-Golgi network in human macrophages and interacts with GGA adaptors. J Leukoc Biol 76:1151-1161.
24. Prevo R, S Banerji, J Ni and DG Jackson. (2004). Rapid plasma membrane-endosomal trafficking of the lymph node sinus and high endothelial venule scavenger receptor/homing receptor Stabilin-1 (FEEL-1/CLEVER-1). J Biol Chem 279:52580-52592.
25. Hansen B, P Longati, K Elvevold, GI Nedredal, K Schledzewski, R Olsen, M Falkowski, J Kzhyshkowska, F Carlsson, et al. (2005). Stabilin-1 and Stabilin-2 are both directed into the early endocytic pathway in hepatic sinusoidal endothelium via interactions with clathrin/AP-2, independent of ligand binding. Exp Cell Res 303:160-173.
26. Kzhyshkowska J, A Gratchev, H Brundiers, S Mamidi, L Krusell and S Goerdt. (2005). Phosphatidylinositide 3-kinase activity is required for Stabilin-1-mediated endosomal transport of acLDL. Immunobiology 210:161-173.
27. Zhang J, A Gratchev, V Riabov, S Mamidi, C Schmuttermaier, L Krusell, E Kremmer, G Workman, EH Sage, et al. (2009). A novel GGA-binding site is required for intracellular sorting mediated by Stabilin-1. Mol Cell Biol 29:6097-6105.
28. Kzhyshkowska J, A Gratchev, C Schmuttermaier, H Brundiers, L Krusell, S Mamidi, J Zhang, G Workman, EH Sage, et al. (2008). Alternatively activated macrophages regulate extracellular levels of the hormone placental lactogen via receptor-mediated uptake and transcytosis. J Immunol 180:3028-3037.
29. Kzhyshkowska J, G Workman, M Cardo-Vila, W Arap, R Pasqualini, A Gratchev, L Krusell, S Goerdt and EH Sage. (2006). Novel function of alternatively activated macrophages: stabilin-1-mediated clearance of SPARC. J Immunol 176:5825-5832.
30. Park SY, MY Jung, SJ Lee, KB Kang, A Gratchev, V Riabov, J Kzhyshkowska and IS Kim. (2009). Stabilin-1 mediates phosphatidylserine-dependent clearance of cell corpses in alternatively activated macrophages. J Cell Sci 122:3365-3373.
31. Rashbaum IG. (2009). The sixth edition: self-directed physiatric education program (SDPEP) 2009. PM R 1 (3 Suppl.):S1-S2.
32. Falkowski M, K Schledzewski, B Hansen and S Goerdt. (2003). Expression of Stabilin-2, a novel fasciclin-like hyaluronan receptor protein, in murine sinusoidal endothelia, avascular tissues, and at solid/liquid interfaces. Histochem Cell Biol 120:361-369.
33. Qian H, S Johansson, P McCourt, B Smedsrod and M Ekblom. (2009). Stabilins are expressed in bone marrow sinusoidal endothelial cells and mediate scavenging and cell adhesive functions. Biochem Biophys Res Commun 390:883-886.
34. Zhou B, JA Weigel, A Saxena and PH Weigel. (2002). Molecular cloning and functional expression of the rat 175- kDa hyaluronan receptor for endocytosis. Mol Biol Cell 13: 2853-2868.
35. Lewis SL, PR Patel, M Palta, DS Yoo and JK Salama. (2016). In reply to Fiorino and Cozzarini. Int J Radiat Oncol Biol Phys 94:860-861.
36. Zhou B, CT McGary, JA Weigel, A Saxena and PH Weigel. (2003). Purification and molecular identification of the human hyaluronan receptor for endocytosis. Glycobiology 13:339-349.
37. Harris EN, SV Kyosseva, JA Weigel and PH Weigel. (2007). Expression, processing, and glycosaminoglycan binding activity of the recombinant human 315-kDa hyaluronic acid receptor for endocytosis (HARE). J Biol Chem 282:2785-2797.
38. Pandey MS, EN Harris, JA Weigel and PH Weigel. (2008). The cytoplasmic domain of the hyaluronan receptor for endocytosis (HARE) contains multiple endocytic motifs targeting coated pit-mediated internalization. J Biol Chem 283:21453-21461.
39. Yannariello-Brown J, B Zhou and PH Weigel. (1997). Identification of a 175 kDa protein as the ligand-binding subunit of the rat liver sinusoidal endothelial cell hyaluronan receptor. Glycobiology 7:15-21.
40. Harris EN and PH Weigel. (2008). The ligand-binding profile of HARE: hyaluronan and chondroitin sulfates a, c, and d bind to overlapping sites distinct from the sites for heparin, acetylated low-density lipoprotein, dermatan sulfate, and CS-E. Glycobiology 18:638-648.
41. Harris EN, BA Baggenstoss and PH Weigel. (2009). Rat and human HARE/Stabilin-2 are clearance receptors for high- and low-molecular-weight heparins. Am J Physiol Gastrointest Liver Physiol 296:G1191-G1199.
42. Li R, A Oteiza, KK Sorensen, P McCourt, R Olsen, B Smedsrod and D Svistounov. (2011). Role of liver sinusoidal endothelial cells and stabilins in elimination of oxidized low-density lipoproteins. Am J Physiol Gastrointest Liver Physiol 300:G71-G81.
43. Park SY, SY Kim, MY Jung, DJ Bae and IS Kim. (2008). Epidermal growth factor-like domain repeat of Stabilin-2 recognizes phosphatidylserine during cell corpse clearance. Mol Cell Biol 28:5288-5298.
44. Miller CM and EN Harris. (2016). Antisense oligonucleotides: treatment strategies and cellular internalization. RNA Dis 3:e1393.
45. Harris EN, JA Weigel and PH Weigel. (2008). The human hyaluronan receptor for endocytosis (HARE/Stabilin-2) is a systemic clearance receptor for heparin. J Biol Chem 283: 17341-17350.
46. Miller, CM, WB Wan, PP Seth, EN Harris (2018). Endosomal escape of ASOs internalized by Stabilin receptors is regulated by Rab5C and EEA1 during endosomal maturation. Nucl Acid Ther 28:86-96.
47. Wang S, H Sun, M Tanowitz, X-H Liang and ST Crooke. (2017). Intra-endosomal trafficking mediated by lysobisphosphatidic acid contributes to intracellular release of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Res 45:5309-5322.
48. Schwartz AL, D Rup and HF Lodish. (1980). Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte. J Biol Chem 255:9033-9036.
49. Pricer WE and G Ashwell. (1971). The binding of desialylated glycoproteins by plasma membranes of rat liver. J Biol Chem 246:4825-4833.
50. Hudgin RL, WE Pricer, G Ashwell, RJ Stockert and AG Morell. (1974). The isolation and properties of a rabbit liver binding protein specific for asialoglycoproteins. J Biol Chem 249:5536-5543.
51. D'Souza AA and PV Devarajan. (2015). Asialoglycoprotein receptor mediated hepatocyte targeting-strategies and applications. J Control Release 203:126-139.
52. Park EI, Y Mi, C Unverzagt, H-J Gabius and JU Baenziger. (2005). The asialoglycoprotein receptor clears glycoconjugates terminating with sialic acidα2,6GalNac. Proc Natl Acad Sci U S A 102:17125-17129.
53. Steirer LM, EI Park, RR Townsend and JU Baenziger. (2009). The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid α2,6- galactose. J Biol Chem 284:3777-3783.
54. Spiess M. (1990). The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry 29:10009-10018.
55. Stockert RJ. (1995). The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 75:591-609.
56. Wall DA, G Wilson and AL Hubbard. (1980). The galactose-specific recognition system of mammalian liver: the route of ligand internalization in rat hepatocytes. Cell 21:79-93.
57. Wall DA and AL Hubbard. (1981). Galactose-specific recognition system of mammalian liver: receptor distribution on the hepatocyte cell surface. J Cell Biol 90: 687-696.
58. Geuze HJ, JW Slot, GJAM Strous, HF Lodish and AL Schwartz. (1983). Intracellular site of asialoglycoprotein receptor-ligand uncoupling: double-label immunoelectron microscopy during receptor-mediated endocytosis. Cell 32: 277-287.
59. Braun JR, TE Willnow, S Ishibashi, G Ashwell and J Herz. (1996). The major subunit of the asialoglycoprotein receptor is expressed on the hepatocellular surface in mice lacking the minor receptor subunit. J Biol Chem 271: 21160-21166.
60. Geffen I, HP Wessels, J Roth, MA Shia and M Spiess. (1989). Endocytosis and recycling of subunit H1 of the asialoglycoprotein receptor is independent of oligomerization with H2. EMBO J 8:2855-2861.
61. Bider MD, R Cescato, P Jeno and M Spiess. (1995). Highaffinity ligand binding to subunit H1 of the asialoglycoprotein receptor in the absence of subunit H2. Eur J Biochem 230:207-212.
62. Tozawa R-I, S Ishibashi, J-I Osuga, K Yamamoto, H Yagyu, K Ohashi, Y Tamura, N Yahagi, Y Iizuka, et al. (2001). Asialoglycoprotein receptor deficiency in mice lacking the major receptor subunit: its obligate requirement for the stable expression of oligomeric receptor. J Biol Chem 276:12624-12628.
63. Meier M, MD Bider, VN Malashkevich, M Spiess and P Burkhard. (2000). Crystal structure of the carbohydrate recognition domain of the H1 subunit of the asialoglycoprotein receptor. J Mol Biol 300:857-865.
64. Geffen I, C Fuhrer, B Leitinger, M Weiss, K Huggel, G Griffiths and M Spiess. (1993). Related signals for endocytosis and basolateral sorting of the asialoglycoprotein receptor. J Biol Chem 268:20772-20777.
65. Katzir Z, N Nardi, I Geffen, C Fuhrer and YI Henis. (1994). Dynamic interactions of the asialoglycoprotein receptor subunits with coated pits. Enhanced interactions of H2 following association with H1. J Biol Chem 269:21568-21575.
66. Ozaki K, R Lee, Y Lee and T Kawasaki. (1995). The differences in structural specificity for recognition and binding between asialoglycoprotein receptors of liver and macrophages. Glycoconj J 12:268-274.
67. Lee RT and YC Lee. (1997). Facile synthesis of a highaffinity ligand for mammalian hepatic lectin containing three terminal n-acetylgalactosamine residues. Bioconjug Chem 8:762-765.
68. Lee YC and RT Lee. (2008). Interactions of oligosaccharides and glycopeptides with hepatic carbohydrate receptors. In: Carbohydrates in Chemistry and Biology. Ernst B, GW Hart and P Sinaý , eds. Wiley-VCH Verlag GmbH, Weinheim, Germany, pp. 549-561.
69. Mammen M, S-K Choi and GM Whitesides. (1998). Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew Chem Int Ed 37:2754-2794.
70. Prakash TP, J Yu, MT Migawa, GA Kinberger, WB Wan, ME Ostergaard, RL Carty, G Vasquez, A Low, et al. (2016). Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes. J Med Chem 59:2718-2733.
71. Migawa MT, TP Prakash, G Vasquez, WB Wan, J Yu, GA Kinberger, ME Ostergaard, EE Swayze and PP Seth. (2016). A convenient synthesis of 5′-triantennary N-acetylgalactosamine clusters based on nitromethanetrispropionic acid. Bioorg Med Chem Lett 26:2194-2197.
72. Nair JK, JL Willoughby, A Chan, K Charisse, MR Alam, Q Wang, M Hoekstra, P Kandasamy, AV Kel'in, et al. (2014). Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust rnai-mediated gene silencing. J Am Chem Soc 136:16958-16961.
73. Matsuda S, K Keiser, JK Nair, K Charisse, RM Manoharan, P Kretschmer, CG Peng, VKi A, P Kandasamy, et al. (2015). SiRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem Biol 10:1181-1187.
74. Rajeev KG, JK Nair, M Jayaraman, K Charisse, N Taneja, J O'Shea, JL Willoughby, K Yucius, T Nguyen, et al. (2015). Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem 16:903-908.
75. Ostergaard ME, J Yu, GA Kinberger, WB Wan, MT Migawa, G Vasquez, K Schmidt, HJ Gaus, HM Murray, et al. (2015). Efficient synthesis and biological evaluation of 5′- GalNac conjugated antisense oligonucleotides. Bioconjug Chem 26:1451-1455.
76. Kinberger GA, TP Prakash, J Yu, G Vasquez, A Low, A Chappell, K Schmidt, HM Murray, H Gaus, et al. (2016). Conjugation of mono and di-galnac sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes. Bioorg Med Chem Lett 26:3690-3693.
77. Schmidt K, TP Prakash, AJ Donner, GA Kinberger, HJ Gaus, A Low, ME Ostergaard, M Bell, EE Swayze and PP Seth. (2017). Characterizing the effect of GalNac and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor. Nucleic Acids Res 45:2294-2306.
78. Tanowitz M, L Hettrick, A Revenko, GA Kinberger, TP Prakash and PP Seth. (2017). Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamineconjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes. Nucleic Acids Res 45:12388-12400.
79. Graham MJ, ST Crooke, DK Monteith, SR Cooper, KM Lemonidis, KK Stecker, MJ Martin and RM Crooke. (1998). In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 286:447-458.
80. Donner AJ, EV Wancewicz, HM Murray, S Greenlee, N Post, M Bell, WF Lima, EE Swayze and PP Seth. (2017). Co-administration of an excipient oligonucleotide helps delineate pathways of productive and nonproductive uptake of phosphorothioate antisense oligonucleotides in the liver. Nucleic Acid Ther 27:209-220.
81. Butler M, RM Crooke, MJ Graham, KM Lemonidis, M Lougheed, SF Murray, D Witchell, U Steinbrecher and CF Bennett. (2000). Phosphorothioate oligodeoxynucleotides distribute similarly in class a scavenger receptor knockout and wild-type mice. J Pharmacol Exp Ther 292:489-496.
82. Ezzat K, Y Aoki, T Koo, G McClorey, L Benner, A Coenen-Stass, L O'Donovan, T Lehto, A Garcia-Guerra, et al. (2015). Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides. Nano Lett 15:4364-4373.
83. Shemesh CS, RZ Yu, HJ Gaus, PP Seth, EE Swayze, FC Bennett, RS Geary, SP Henry and Y Wang. (2016). Pharmacokinetic and pharmacodynamic investigations of ION-353382, a model antisense oligonucleotide: using alpha-2-macroglobulin and murinoglobulin double-knockout mice. Nucleic Acid Ther 26:223-235.
84. Guvakova MA, LA Yakubov, I Vlodavsky, JL Tonkinson and CA Stein. (1995). Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J Biol Chem 270:2620-2627.
85. Viney NJ, JC van Capelleveen, RS Geary, S Xia, JA Tami, RZ Yu, SM Marcovina, SG Hughes, MJ Graham, et al. (2016). Antisense oligonucleotides targeting apolipoprotein( a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 388:2239-2253.